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Case report
The patient is an 84-year-old male with a history of  pros-
tate carcinoma. At the time of  diagnosis, he had a Gleason 
sum of  5 and received radioactive seed brachytherapy. Due 
to subsequent biochemical failure (rising PSA) approxi-
mately eight years later, he presented for a nuclear medi-
cine bone scan, which showed diffuse osteoblastic meta-
static skeletal disease (Fig. 1). The patient was started on 
luteinizing hormone-releasing hormone (LHRH) agonist 
and antiandrogen therapy at that time and returned for a 
followup bone scan approximately six months after initia-
tion of  continuous hormone deprivation therapy (Fig. 2). 
For both the pretherapy and post-therapy bone scans, the 
patient was injected intravenously with approximately 25 
mCi of  Technetium-99m MDP. Anterior and posterior 
planar images of  the body were obtained four hours after 
injection. The pretherapy bone scan showed multiple areas 
of  intense focal radiotracer uptake consistent with osseous 
metastases including the sternum, multiple bilateral ribs, 
multiple levels of  the thoracic and lumbar spine, bilateral 
iliac bones, acetabula, sacrum, and left superior pubic ra-
mus. Intense focal uptake in the glenoid of  bilateral scapula 
was also suspicious for metastatic involvement. Increased 
uptake at the left knee joint and medial knee compartment 
on the right was most likely related to degenerative change.
The post-therapy bone scan revealed a remarkable mixed 
pattern of  interval change. The majority of  identified foci 
of  intensely increased uptake throughout the upper tho-
racic spine demonstrated considerable interval decrease in 
intensity and extent along with concordant decrease in in-
tensity and extent of  multiple foci of  increased uptake in-
volving the anterior and posterior upper ribs bilaterally. 
In contrast to the above findings, there was interval pro-
gression of  foci of  increased uptake involving the lower ribs 
bilaterally, lower thoracic spine, lumbar spine, and pelvis, 
including significant interval progression involving the sa-
crum, right iliac bone, and right ischium; and significant 
interval increase in intensity and extent of  uptake involving 
the right acetabulum and surrounding pelvic bones. In ad-
dition, there was interval progression of  increased uptake 
involving the left acetabulum and surrounding pelvic bones. 
There was interval development of  three new foci of  in-
creased uptake involving right femoral neck, right lesser 
trochanter, and right proximal medial femoral shaft. Again 
there were findings suggestive of  degenerative disease in-
volving the knee joints bilaterally.
In summary, when compared to the pretherapy bone 
scan, the post-therapy bone scan demonstrated an overall 
mixed pattern of  interval change, with significant interval 
improvement involving the upper thoracic spine and upper 
ribs bilaterally in contrast to significant interval progression 
in the lower thoracic spine, lumbar spine, pelvis, and right 
femur, as described in detail above.
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We report a marked geographically inconsistent response of  prostate cancer skeletal metastases to an-
drogen deprivation therapy. Such inconsistent response to therapy has not been described previously in 
the literature and should be correlated with individual patient history. Further understanding of  the 
mechanism of  geographic responses to hormone deprivation therapy may have implications in the tar-
geting of  specific regions of  disease for treatment in the future. 
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Figure 2. 84-year-old male with prostate cancer. Nuclear 
medicine bone scan approximately six months after con-
tinuous hormone deprivation therapy demonstrates a mixed 
pattern of improvement and progression of skeletal metas-
tases. Improvement of skeletal metastases is best appreci-
ated in the upper thoracic region. The left image shows the 
anterior projection, and the right image shows the posterior 
projection. 
Figure 1. 84-year-old male with prostate cancer. After rising 
PSA, nuclear medicine bone scan shows diffuse disease 
metastatic to the skeleton. The left image shows the ante-
rior projection, and the right image shows the posterior 
projection. 
Discussion
Bone is one of  the most common sites of  metastasis from 
prostate cancer, and bone metastasis greatly affects the 
quality of  life and prognosis of  patients with prostate can-
cer. Androgen deprivation therapy (ADT) is a mainstay of  
prostate cancer management for patients with evidence of  
systemic disease (1). ADT consists of  gonadotropin-
releasing hormone (GnRH) agonist administration (typi-
cally, intramuscular leuprolide or subcutaneous implanted 
goserelin) with or without an antiandrogen (bicalutamide, 
flutamide, or nilutamide) or, less commonly, bilateral or-
chiectomy (2, 3). All current forms of  androgen deprivation 
function by reducing the ability of  androgen to activate the 
androgen receptor, whether through lowering levels of  an-
drogen or by blocking androgen-androgen receptor 
binding. 
Without a detailed patient history, we initially postulated 
that the interval improvement of  metastatic skeletal disease 
in the upper thoracic spine and upper ribs bilaterally in 
contrast to significant interval progression in the lower tho-
racic spine, lumbar spine, pelvis, and right femur could 
represent radiation therapy (port) to the upper chest. Upon 
confirmation, the patient had not received radiation ther-
apy, but only LHRH/antiandrogen treatment since the 
pretherapy bone scan. We did confirm that the patient had 
a long sports career as a baseball pitcher and still actively 
pitches. With androgen receptor function shown to be es-
sential for androgen effects on the male skeleton in murine 
models and humans (4, 5), we hypothesize that the patient’s 
increased repetitive use of  the upper extremities during his 
pitching career has possibly increased vascularity to the 
upper thorax and allowed for better delivery of  antiandro-
gen agent to the upper thoracic skeleton relative to the rest 
of  the body. This might explain the contradictory im-
provement of  metastatic disease in the upper thorax versus 
progression of  metastatic disease elsewhere in the body. 
Alternative explanations for the discrepant response to 
therapy seen in this patient may be the transformation of  
certain regions of  disease to an androgen-independent/
hormone-refractory tumor that no longer responds to stan-
dard hormone deprivation therapy, or preferential healing 
of  certain metastatic sites for other unexplained reasons. If  
indeed this patient’s paradoxical response to therapy repre-
sented transformation to androgen-independent prostate 
cancer, alternative treatments including docetaxel may be 
indicated; however, the reason for such geographic trans-
formation of  tumor must be further investigated (6). In ad-
dition, it has been recognized that a bone scan to determine 
treatment efficacy in patients with prostate cancer and bone 
metastases should be performed after a minimum of  three 
months (7). Because bone scans assess changes in the bone 
itself  and not the tumor directly, it is possible that an ap-
parent false pattern of  worsening (flare phenomenon) may 
reflect healing response of  bone and not true progression of 
disease. In our patient, the post-therapy bone scan was ob-
tained at six months, making flareup less likely. 
To our knowledge, this is the first study to report such 
significant contradictory change of  prostate cancer bone 
metastases on bone scan following hormone deprivation 
therapy. Further understanding of  the mechanism of  geo-
graphic responses to hormone deprivation therapy may 
have implications in targeting specific regions of  disease for 
treatment in the future. Perhaps tagging a monoclonal an-
tibody (such as that used in ProstaScint imaging) with a 
radioactive isotope such as Ytrium-90 or Iodine-131 (simi-
lar to the concept of  Bexxar and Zevalin) may be helpful in 
treating patients who do not respond to ADT. The delivery 
of  antiangiogenesis agents via a similar method may also be 
more effective in treating metastatic disease that does not 
respond to initial hormone deprivation therapy. 
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